The present disclosure is generally directed to methods of preventing, reducing the risk of developing, or treating a blood disorder (e.g., hematologic disorders, etc. Condensate hemolytic anemia (condensate disease), cold antibody hemolytic anemia, ABO incompatible acute hemolytic reaction, thermal agglutinin hemolytic anemia, warm antibody hemolytic anemia, warm antibody autoimmune hemolytic anemia (WAIHA), autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, antiphospholipid syndrome, Evans syndrome, and the like. Red blood cell isoimmunity, Verpet syndrome, neonatal isoimmune thrombocytopenia, heparin-induced thrombocytopenia (HIT), heparin-induced thrombocytopenia and thrombus (HITT), thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenic purpura (ITP), thrombocytopenia, thrombus, vasculitis, lupus nephritis, systemic lupus erythematosus (SEE), and the like. The present invention relates to methods for treating a subject (e.g., glomerulonephritis, anti-phospholipid antibody syndrome (APS), infection or drug-induced hematological disorder) comprising administering to the subject an inhibitor of the complement pathway.